Schaeffer's Top Stock Picks for '25

Apricus Biosciences Eyes New Record Lows After FDA Rejection

The FDA cited safety concerns in its latest rejection of APRI's erectile dysfunction cream

Feb 16, 2018 at 8:58 AM
facebook X logo linkedin


Shares of San Diego-based Apricus Biosciences Inc (NASDAQ:APRI) are getting hammered this morning, after the U.S. Food and Drug Administration (FDA) once again declined to approve its Vitaros erectile dysfunction cream. Regulators cited safety concerns regarding an ingredient in the drug known as DDAIP.HCI, and also pointed to "deficiencies related to Chemistry, Manufacturing and Control," per a company statement.

Apricus CEO Richard Pascoe said the company is "disappointed" with the outcome of the FDA review, and expects to provide an update on the drug's future prospects in early March. Vitaros is already widely available outside the U.S. market, including Mexico, Canada, and throughout Europe.

APRI has tanked more than 73% in electronic trading, after settling Thursday's session at $3.19. The pre-market drop has Apricus shares trading south of the $1 mark, and on pace to slice through recent support at their 20-day, 40-day, and 80-day moving averages. In fact, the drug stock is at risk of setting a new all-time low, with the equity hovering just below last May's nadir of $0.86 in electronic action.

Short sellers will likely be pleased with APRI's early bearish momentum. Short interest on the stock ramped up by 13.4% during the past two reporting periods, and now accounts for 7.6% of the stock's available float. Of course, with the shares down so drastically in pre-market trading, short selling is likely to be restricted today -- and if any of these bears decide to take profits, the resulting buying pressure could help APRI find a floor.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?